CN Patent

CN110996913A — 新的贝利司他口服制剂

Assigned to Akrotec Biopharmaceutical Co ltd · Expires 2020-04-10 · 6y expired

What this patent protects

本申请涉及适用于口服给药的新的贝利司他制剂、其制备方法、包含所述制剂的药物组合物及其用途。

USPTO Abstract

本申请涉及适用于口服给药的新的贝利司他制剂、其制备方法、包含所述制剂的药物组合物及其用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN110996913A
Jurisdiction
CN
Classification
—
Expires
2020-04-10
Drug substance claim
No
Drug product claim
No
Assignee
Akrotec Biopharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.